Pielotax Research Overview (also known as Pielotax peptide, Ala-Glu-Asp-Arg tetrapeptide, Khavinson renal bioregulator)
A peptide studied for kidney (nephron) structural integrity support, renal filtration capacity, and recovery from chronic renal stress. Research interest includes kidney health in aging and detoxification-burden models.
What Is Pielotax?
Pielotax is a tetrapeptide bioregulator developed by Professor Vladimir Khavinson targeting kidney (renal) tissue. It belongs to the Khavinson system of organ-specific peptide bioregulators and is designed to restore normal functional gene expression in renal cells — specifically nephrons, the functional filtration units of the kidney — that decline in activity with aging.
Renal Aging
Kidney function declines predictably with age: GFR decreases by approximately 1 mL/min/year after age 40, glomerulosclerosis progresses, tubular secretion capacity falls, and the kidney's ability to concentrate urine diminishes. By age 80, most individuals have lost 30–40% of their renal functional reserve. Pielotax is designed to slow this decline by restoring normal nephron cell gene expression.
Research Applications
Animal studies have demonstrated improved kidney histology scores, reduced fibrosis markers, better preservation of GFR parameters, and decreased tubular injury markers in aged animals treated with Pielotax. It is used in Russian anti-aging bioregulator protocols targeting renal health and is sometimes combined with Crystagen (bladder bioregulator) and Vesilut for comprehensive urological system support.
Mechanism of Action
Tissue-selective renal metabolism normalization: Pielotax (peptide complex A-9) acts selectively on kidney tissue cells, regulating metabolic processes and normalizing renal function. Experimental and clinical data demonstrate activation of metabolism in kidney tissues and intensification of secretory function, reflected in improved biochemical markers — urea, uric acid, and creatinine — in gouty nephropathy subjects. Pielotax also exhibits anti-oxidative properties, reducing peroxide oxidation in renal tissue and lowering oxidative stress burden on nephrons. The result is increased functional reserve capacity and improved adaptation to environmental stress and metabolic load.
Short signaling peptides and gene regulation: Pielotax's low-molecular peptides (≤5000 Da) are proposed to interact directly with DNA promoter regions in renal cells — inducing local unwinding of the double helix, activating RNA polymerase, and initiating transcription of kidney-specific proteins. This nuclear-active mechanism aligns with the broader Khavinson bioregulator framework, framing Pielotax as an epigenetic modulator that restores youthful gene expression programs in aging nephron cells rather than acting through a classical receptor pathway.
Cell renewal and anti-apoptotic effects: Experimental models show that Pielotax increases synthesis of the kidney cell-division protein Ki67 by 2.2×, enhancing proliferative activity, while reducing expression of pro-apoptotic p53 by approximately 20% in kidney cells. Together these changes stimulate cell renewal in renal tissue, supporting regeneration under chronic nephrotoxic stress, ischemic injury, and age-related decline. Functional effects develop over 15–30 day courses and can persist for months after the course ends, consistent with gene-expression and protein-synthesis changes outlasting plasma peptide exposure.
Research Indications
Gouty Nephropathy
A clinical study in middle-aged patients with gouty nephropathy showed 78% of patients experienced a decrease in clinical nephropathy signs, with improvements in well-being, sleep normalization, reduced joint pain, and favorable changes in blood and urine laboratory markers. Pielotax was well tolerated — no side effects, complications, or drug dependence reported. Authors recommend it as a medical-preventive adjunct to symptomatic and pathogenetic therapy for gouty nephropathy.
Nephropathy Adjunctive Therapy (Clinical)
Russian clinical practice data support Pielotax as a component of complex therapy for various kidney diseases, normalizing metabolism and function of kidney cells. Clinical protocols combine it with standard nephropathy medications (allopurinol, RAAS blockers) without reported major interactions.
Gouty NephropathySupported Research
Nephroprotection in Experimental Injury Models
Experimental data show nephroprotective effects in models of ischemic kidney injury, gentamicin nephropathy, and cisplatin-induced acute renal failure, supporting recovery of both kidney structure and function. Cell renewal markers (Ki67 ↑ 2.2×; p53 ↓ 20%) confirm regenerative activity in renal tissue models.
Renal Aging and GFR Preservation
Long-term animal bioregulator studies report 20–40% increases in mean lifespan when short signaling peptides are used from mid-life onward. Human preventive use data from Russian literature associates periodic peptide courses with rehabilitation of physiological functions over 6–12 year follow-up periods, though study methodology and controls are limited.
Nephroprotection in Experimental Injury ModelsPreliminary Data
CKD Support and Functional Reserve Restoration
Contemporary integrative clinicians discuss Pielotax as a potential adjunct in CKD management, aiming to restore natural kidney function and enhance effects of other medications. This application is experimental — no controlled trials in CKD populations exist outside Russian observational literature.
CKD Support and Functional Reserve RestorationPreclinical Only
Research Protocols (Educational Only)
Disclaimer
Pielotax is not an FDA-approved drug. It is marketed as a dietary supplement / biologically active food additive and used as an RUO nephroprotective peptide. Dosing below is drawn from Russian clinical reports and modern integrative protocols — not Western regulatory guidance. Cycle and maintenance patterns differ significantly from injectable peptides.
| Goal / Context | Dose | Frequency / Duration | Route |
|---|
| Gouty nephropathy / nephropathies | 10–20 mg (1–2 caps) | 2–3× daily, 15–30 days | Oral |
| Intensive kidney repair (modern protocol) | 20 mg (2 caps) | Once daily, 30 days | Oral |
| Maintenance — every 3 months | 20 mg (2 caps) | Once daily, 10 days | Oral |
| Higher-need monthly maintenance | 20 mg (2 caps) | Once daily, 10 days/month | Oral |
| Lingual / sublingual support | ~10 mg (~18 drops) | Once daily, 1–3 months | Sublingual |
Cycle Pattern
15–30 days on → 3–6 months off (intensive); or 10 days on → monthly maintenance for ongoing support. Repeated courses are the norm for this Khavinson Cytomax product — short functional improvements motivate periodic repeats. Plasma half-life is short (minutes–hours, typical of low-molecular peptides); functional renal effects develop over the course and may persist for months before gradual washout.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Oral Intensive | 20 mg (2 capsules) | Once daily, 15–30 min before meals | Oral |
| Oral Maintenance | 20 mg (2 capsules) | Once daily | Oral |
| Sublingual | ~10 mg | Once daily | Sublingual |
Peptide Interactions
Often paired with Pielotax for full urinary tract protection — kidney + bladder. The combination addresses both filtration (Pielotax) and lower urinary tract function (Chitomur/Crystagen) in Russian bioregulator stacks.
Included in complex kidney disease therapy schemes alongside Ovagen for metabolic and liver support. Conceptually addresses multiple organ systems implicated in metabolic nephropathy.
Recommended to improve renal microcirculation and nutrient delivery to nephrons, conceptually enhancing Pielotax's tissue-level effects. No formal interaction data.
Pielotax has been used in combination with symptomatic and pathogenetic kidney therapies in clinical reports; no major adverse interactions reported. Physician oversight recommended when combining with any active medication regimen.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Well tolerated in published clinical use — the gouty nephropathy study reported no side effects, complications, or drug dependence at oral doses. Acute toxicity testing in animals found very high doses non-toxic, suggesting a wide safety margin.
No dependence or withdrawal phenomena — consistent with the Khavinson bioregulator family broadly.
Combine with standard medications cautiously — Pielotax has been used alongside allopurinol and RAAS blockers without major interactions reported; physician oversight is recommended when any active medication regimen is involved.
Long-term effects of DNA-interactive short peptides are unknown — potential off-target effects on non-renal tissues or cancer risk have not been rigorously evaluated in long-term studies.
Evidence base is limited — the bulk of data comes from small, non-randomized Russian clinical and animal studies with limited Western replication. No large RCTs exist.
Not FDA-approved — classified as a dietary supplement / biologically active food additive. Not intended for use as a clinical drug outside a supervised research or integrative medicine context.
Do Not Use If:
Active acute renal failure or severe CKD without specialist medical supervision
Use as a replacement for prescribed nephropathy medications — Pielotax is adjunctive, not a substitute for standard of care
Pregnancy or breastfeeding — no safety data exists for these populations
Seek Medical Attention If:
Persistent injection site reactions (redness, pain, or swelling beyond 48 hours)
Signs of allergic reaction (hives, difficulty breathing, or facial swelling)
Severe or unusual symptoms following administration
Always consult a licensed physician before and during use
Urinary changes or new kidney-related symptoms
Quality Indicators
Verified
Label identifies peptide complex A-9 (kidney peptides), 10 mg per capsule
Authentic Pielotax capsules contain 10 mg peptide complex A-9 per capsule; the standard daily dose is 2 capsules (20 mg). Lingual products specify 10–10.5 mg per 1 mL (~18 drops). Source identification should be traceable to bovine kidney parenchyma of young animals.
Verified
Produced under Khavinson-associated or licensed technology
Pielotax is a proprietary Khavinson Institute product. Authentic sourcing from licensed producers or authorized distributors is the primary quality guarantee for a compound without widespread independent analytical verification.
Caution
Storage: cool and dry; check expiration and batch
Capsules should be stored in a cool, dry location per label. Lingual solutions are often refrigerated. Check batch and expiration before use — short peptides are susceptible to degradation under heat and moisture.
CAUTION — NOT RECOMMENDED
Products lacking documented peptide source, content per unit, or COA
Non-licensed products without documented A-9 peptide complex source, per-capsule content disclosure, or certificate of analysis carry unpredictable identity and potency risk. The supplement market for Khavinson bioregulators has quality variability.
Reported Research Timeline
01During active course (Days 1–15 to 1–30) (reported in cited studies): Pielotax (Ala-Glu-Asp-Arg tetrapeptide) targets renal tubular and glomerular epithelial cells through the Khavinson epigenetic bioregulation mechanism. Research outcomes tracked during active courses include renal function markers (serum creatinine, eGFR, BUN), urinary protein levels, and inflammatory markers associated with renal aging. Measurable effects on renal biomarkers typically begin by the second week of an intensive oral course.
02Weeks 4–6 post-course (reported in cited studies): Improved renal filtration parameters and reduced microalbuminuria are the primary reported findings in Khavinson clinical observational data. Subjects with mildly compromised baseline renal function show the most pronounced improvements. Urinary protein normalization and stabilization of serum creatinine are the benchmark outcomes.
03Months 1–3 (sustained renal support) (reported in cited studies): The epigenetic normalization pattern from the active course maintains its effect for 3–6 months post-treatment. Khavinson longitudinal data show slowed progression of age-related GFR decline in subjects receiving regular Pielotax courses compared to control groups over 3+ year observation windows.
04Long-term (repeated courses) (reported in cited studies): Semi-quarterly or annual Pielotax use in Khavinson longevity protocols corresponds to improved renal aging trajectories across multi-year cohort studies. Combined use with other Khavinson organ-specific bioregulators (Vesugen for vascular, Livagen for hepatic) provides complementary multi-organ support in comprehensive geroprotective regimens.
Research Citations
- Peptide bioregulators as a new class of geroprotectors: from laboratory research to clinical studies
Khavinson V, Linkova N, Diatlova A, Trofimova S — Biomedicines, 2021
- Peptide regulation of aging — Khavinson bioregulator family review
Khavinson VKh, Linkova NS et al. — Bull Exp Biol Med, 2013
- Short peptides regulate gene expression, protein synthesis and replicative lifespan of human fibroblasts
Khavinson VKh et al. — Bull Exp Biol Med, 2014
- Correction of impaired glucose tolerance using tetrapeptide in old female rhesus monkeys — Khavinson bioregulator NHP model
Goncharova ND, Ivanova LG, Oganyan TE — Adv Gerontol, 2015
- Geroprotective effects of peptide bioregulators in aging: current status and prospects
Khavinson VKh, Linkova NS et al. — Adv Gerontol, 2023
Research Focus
Kidney function, Renal tissue restoration, Anti-aging, Nephroprotection, Urinary health
Frequently Asked Questions
What should researchers watch for with Pielotax?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Pielotax?
During active course (Days 1–15 to 1–30) (reported in cited studies): Pielotax (Ala-Glu-Asp-Arg tetrapeptide) targets renal tubular and glomerular epithelial cells through the Khavinson epigenetic bioregulation mechanism. Research outcomes tracked during active courses include renal function markers (serum creatinine, eGFR, BUN), urinary protein levels, and inflammatory markers associated with renal aging. Measurable effects on renal biomarkers typically begin by the second week of an intensive oral course.
How is Pielotax typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →